Current Value Frameworks

FrameworkFactors consideredPurposeCosts measured?Perspective
ASCO FrameworkNet Health Benefit: Clinical Benefit (OS > PFS > RR), Toxicity, Extended SurvivalComparison of two regimens that have been reported in a randomized clinical trialNoPatient
ESMO-MCBSMagnitude of Clinical Benefit: Prognosis of Condition, Clinical Benefit (OS, PFS), Long-term Survival (HR, RR), Quality of Life, ToxicityComparison of magnitude of benefit of regimens with reported comparative research outcomesNoSocietal
NCCN Evidence BlocksEfficacy, Safety, Quality of Evidence, Consistency of Evidence, AffordabilityVisual representation of key factors that provide information about the value of the recommendations within the guidelinesYesPatient
MSKCC Drug AbacusEfficacy, Cost Toxicity, Treatment Novelty, Costs of Development, Rarity of Disease, Population Burden of ConditionIntended to provide information regarding the proper pricing of new drugs in the marketYesSocietal
ICER Value FrameworkIncremental Cost - Effectiveness Ratio:Costnew−CoststandardEffectivenessnew−Effectivenessstandard\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \frac{\mathrm{Cos}{\mathrm{t}}_{\mathrm{new}}-\mathrm{Cos}{\mathrm{t}}_{\mathrm{s}\mathrm{tandard}}}{\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{new}}-\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{s}\mathrm{tandard}}} $$\end{document}Comparison of two treatments based on efficacy and costYesSocietal

Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard ratio, RR Response rate